Journal Article

FZJ-2020-00430

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

Ceccon, G. ; Wollring, M. ; Brunn, A. ; Deckert, M. ; Waldschmidt, D. ; Fink, G. R.FZJ* ; Galldiks, N. (Corresponding author)FZJ*

2020
Karger Basel

This record in other databases:    

Please use a persistent id in citations: http://hdl.handle.net/2128/23986  doi:10.1159/000504697

Abstract: Leptomeningeal carcinomatosis is an extremely rare, but devastating complication in pancreatic cancer patients with a poor prognosis despite multimodal treatment. We present a 51-year-old male patient with the very rare condition of leptomeningeal carcinomatosis originating from pancreatic cancer. He presented to our hospital with severe headache and neck stiffness 30 months after systemic chemotherapy. Cerebral and spinal MRI as well as cerebrospinal fluid examination confirmed the diagnosis of leptomeningeal carcinomatosis. The patient responded to gemcitabine plus nab-paclitaxel in terms of elimination of tumor cells from the CSF and concurrent clinical improvement for 3 months. The observed findings suggest that the combination of gemcitabine plus nab-paclitaxel is potentially effective in affected cerebrospinal fluid of pancreatic carcinoma patients.

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)

Research Program(s):

1. 572 - (Dys-)function and Plasticity (POF3-572) (POF3-572)

Appears in the scientific report 2020

---

Database coverage:
; ; ; ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Emerging Sources Citation Index ; PubMed Central ; SCOPUS ; Web of Science Core Collection

---